CLINICAL IMPLEMENTATION OF A NOVEL HIGH-THROUGHPUT SCREEN OF PRIMARY LEUKEMIA CELLS TO PERSONALIZE THERAPY FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

被引：0
|
作者：
Frattini, M. [1 ]
Shum, D. [1 ]
Heaney, M. [1 ]
Brentjens, R. [1 ]
Maslak, P. [1 ]
Jurcic, J. [1 ]
Djaballah, H. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0048
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [41] Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia
    Dinner, Shira
    Lee, Daniel
    Liedtke, Michaela
    LEUKEMIA & LYMPHOMA, 2014, 55 (08) : 1715 - 1724
  • [42] High dose cytarabine and cyclophosphamide (hAC) regimen for relapsed or refractory acute myeloid leukemia (AML): a retrospective monocentric analysis
    Fix, P.
    Fricke, H-J
    Spies-Weisshart, B.
    La Rosee, P.
    Hochhaus, A.
    Scholl, S.
    ONKOLOGIE, 2010, 33 : 138 - 139
  • [43] G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
    Becker, Pamela S.
    Estey, Elihu
    Petersdorf, Stephen
    Storer, Barry E.
    Appelbaum, Frederick R.
    BLOOD, 2009, 114 (22) : 816 - 816
  • [44] STROMAL CELL SUPPORTED HIGH-THROUGHPUT SCREENING OF PRIMARY ACUTE MYELOID LEUKEMIA CELLS FOR ASSESSING SENSITIVITY TO CYTOTOXIC DRUGS
    Karjalainen, R.
    Pemovska, T.
    Yadav, B.
    Wennerberg, K.
    Heckman, C.
    ANNALS OF HEMATOLOGY, 2013, 92 : S17 - S18
  • [45] High-Throughput Validation of Mutations Identified in Primary Leukemia Cells
    Degnin, Michelle
    Tognon, Cristina E.
    Eide, Christopher A.
    Wilmot, Beth
    McWeeney, Shannon K.
    Bottomly, Daniel
    Smith, Rebecca
    Druker, Brian J.
    BLOOD, 2016, 128 (22)
  • [46] Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: Novel agents and approaches currently in clinical trials
    Sasine, Joshua P.
    Schiller, Gary J.
    BLOOD REVIEWS, 2015, 29 (01) : 1 - 9
  • [47] Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML)
    van den Heuvel-Eibrink, MM
    Wiemer, EAC
    Kuijpers, M
    Pieters, R
    Sonneveld, P
    LEUKEMIA, 2001, 15 (05) : 855 - 856
  • [48] Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML)
    MM van den Heuvel-Eibrink
    EAC Wiemer
    M Kuijpers
    R Pieters
    P Sonneveld
    Leukemia, 2001, 15 : 855 - 856
  • [49] Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)
    MM van den Heuvel-Eibrink
    EAC Wiemer
    A Prins
    JPP Meijerink
    PJM Vossebeld
    B van der Holt
    R Pieters
    P Sonneveld
    Leukemia, 2002, 16 : 833 - 839
  • [50] Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)
    van den Heuvel-Eibrink, MM
    Wiemer, EAC
    Prins, A
    Meijerink, JPP
    Vossebeld, PJM
    van der Holt, B
    Pieters, R
    Sonneveld, P
    LEUKEMIA, 2002, 16 (05) : 833 - 839
12345